Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-small cell lung cancer
Biotech
AstraZeneca, Daiichi pull lung cancer BLA for Enhertu follow-up
After considering feedback from the FDA, the companies have voluntarily withdrawn the non-squamous NSCLC application and submitted a fresh BLA.
James Waldron
Nov 12, 2024 5:27am
FDA puts partial hold on BioNTech-OncoC4 phase 3 trial
Oct 18, 2024 12:55pm
Black Diamond reshuffles execs, drops phase 1 lung cancer drug
Oct 8, 2024 5:36am
Merck, Daiichi ADC hits goal in phase 3 lung cancer study
Sep 17, 2024 7:13am
AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail
Sep 10, 2024 6:00am
Boehringer, Bayer advance lung cancer meds toward Enhertu battle
Sep 9, 2024 4:43pm
